Brief: Median Technologies Announces Lung Nodule Detection Performance For Ibiopsy® Lung Cancer Screening

Median Technologies SA

05/01/2022 16:54

Jan 5 (Reuters) - Median Technologies SA  ALMDT.PA :
    * MEDIAN TECHNOLOGIES ANNOUNCES OUTSTANDING LUNG NODULE
DETECTION
(CADE1) PERFORMANCE FOR IBIOPSY® LUNG CANCER SCREENING
    * AFTER DETECTION (CADE), DIAGNOSTIC COMPONENT (CADX) OF
IBIOPSY®
LCS CHARACTERIZES NODULES AS MALIGNANT OR BENIGN. ITS
SENSITIVITY/SPECIFICITY LEVELS WERE ANNOUNCED IN 2021 AND ARE
STILL UNPARALLELED TODAY
    * PARTICULARLY HIGH SENSITIVITY OF IBIOPSY® LCS IS A
PREREQUISITE
FOR IMPLEMENTING A RELIABLE DETECTION AND DIAGNOSIS (CADE/CADX)
SOLUTION FOR LUNG CANCER SCREENING PROGRAMS
    * IBIOPSY® LUNG CANCER SCREENING (LCS) DETECTION PERFORMANCE
REACHES 94.9% SENSITIVITY FOR A FALSE POSITIVE RATE OF 1 PER CT
SCAN, A PERFORMANCE SUPERIOR TO THAT OF LUNG CADE SYSTEMS
CURRENTLY ON MARKET

Source text for Eikon:  ID:nBw1x1D7Ga 
Further company coverage:  ALMDT.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))